MagnetisMM-6: Excellent early results of elranatamab in MM

Preliminary data from the MagnetisMM-6 part 1 study displayed promising efficacy data for the combination of elranatamab, daratumumab, and lenalidomide in patients with newly diagnosed transplant-ineligible multiple myeloma (MM). No unexpected safety issues were observed, supporting further evaluation of this treatment regimen.

The MagnetisMM-6 study investigated the combination of the BCMA-CD3 bispecific antibody elranatamab added to lenalidomide and daratumumab in patients with transplant-ineligible, previously untreated MM. Part 1 of the study evaluated the optimal dose of the experimental treatment regimen. Dr Meletios Dimopoulos (University of Athens, Greece) presented findings of cohort G, which included 37 patients who were exposed to 76 mg elranatamab, subcutaneously administered every 4 weeks, plus lenalidomide and daratumumab [1].

The most common grade 3 or 4 treatment-emergent adverse events were haematologic toxicity (78.4%) and infections (18.9%). Cytokine release syndrome was observed in 62.2% of the patients, but these were all grade 1 or 2 events. “One patient died from a Candida pneumonia infection,” mentioned Dr Dimopoulos. “Other grade 3 or 4 infections were urinary tract infections, cytomegalovirus reactivation, and pneumonia.”

Except for the patient who had deceased early, all patients responded to therapy (97.3%) after a median follow-up of 7.9 months. In addition, 27.0% of the patients reached at least a complete response. “The follow-up time was short and we expect that the responses will deepen over time,” commented Dr Dimopoulos.

The initial results from the MagnetisMM-6 part-1 dose level G indicated that the combination of elranatamab (every 4 weeks), daratumumab and lenalidomide is effective and manageable in transplant-ineligible, untreated MM. “MagnetisMM-6 part 2, which is a randomised phase 3 study, will evaluate dose level G from part 1,” Dr Dimopoulos concluded his talk.

1. Dimopoulos M-A, et al. Elranatamab in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma not eligible for transplant: initial results from MagnetisMM-6 Part 1. S206, EHA2025 Congress, 12–15 June, Milan, Italy.

Copyright ©2025 Medicom Medical Publishers



Posted on 2 September 20252 September 2025